Companies
Jellagen
producing jellyfish-derived Collagen Type Zero, formed a strategic partnership with US-based Royal Biologics in early 2026 to commercialize the material for the North American regenerative-medicine market, covering wound care and tissue-engineering applications.
- Country
- United Kingdom
jellyfish-derived
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| fibers-textiles | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Headcount | 18 employees | bringo.co.uk · jellagen.co.uk · uk.globaldatabase.com |
| Certification | ISO 13485:2016 certification | jellagen.co.uk |
| Production site | A 10,000 square-foot R&D and manufacturing facility in Cardiff, Wales | jellagen.co.uk · mdpi.com |
| Capacity | Potential to be manufactured from any jellyfish species at huge scale medium confidence | jellagen.co.uk |
| Regulatory approval | Currently in product development toward human trials and regulatory filing medium confidence | jellagen.co.uk |
Independent sources: bringo.co.uk · mdpi.com · uk.globaldatabase.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Recombinant collagen & gelatin | fibers-textiles | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.